The following information contains verifiable peer-reviewed manuscripts and abstracts on the use of Immunomedics compounds in development. Links to PubMed and other original sources are provided, where available
Kalinsky K, Diamond JR, Vahdat LT, et al. Sacituzumab Govitecan in Previously Treated Hormone Receptor-Positive/HER2-Negative Metastatic Breast Cancer: Final Results from a Phase 1/2 , Single-Arm, Basket Trial. Ann Oncol. 2020; S0923-7534(20)42445-7.
Santin AD, Komiya T, Goldenberg DM, et al. Sacituzumab govitecan (SG) in patients (pts) with previously treated metastatic endometrial cancer (mEC): results from a phase 1/2 study. J Clin Oncol. 2020; 38 (suppl; abstr 6081)
Tagawa ST, Faltas M, Lam ET, et al. Sacituzumab govitecan (IMMU-132) in patients with previously treated metastatic urothelial cancer (mUC): Results from a phase I/II study. J Clin Oncol. 2019;39(suppl 7S):abstr 354.
Bardia A, Diamond JR, Vahdat LT, et al. Efficacy of sacituzumab govitecan (anti-Trop-2-SN-38 antibody-drug conjugate) for treatment-refractory hormone-receptor positive (HR+)/HER2- metastatic breast cancer (mBC). J Clin Oncol. 2018;36(15 suppl):1004.
Ocean AJ, Starodub AN, Bardia A, et al. Sacituzumab govitecan (IMMU-132), an anti-Trop-2-SN-38 antibody-drug conjugate for the treatment of diverse epithelial cancers: safety and pharmacokinetics. Cancer. 2017;123:3843-3854.
Gray JE, Heist RS, Starodub AN, et al. Therapy of small cell lung cancer (SCLC) with a topoisomerase-I-inhibiting antibody-drug conjugate (ADC) targeting Trop-2, sacituzumab govitecan. Clin Cancer Res. 2017;23:5711-5719.
Starodub AN, Ocean AJ, Shah MA, et al. First-in-human trial of a novel anti-Trop-2 antibody-SN-38 conjugate, sacituzumab govitecan, for the treatment of diverse metastatic solid tumors. Clin Cancer Res. 2015;21:3870-3878.
Grivas P, Sternberg CN, Agarwal N, et al. TROPHY-U-01 Cohort 3: Sacituzumab Govitecan (SG) and Pembrolizumab (Pembro) in Patients (pts) With Progression or Recurrence of Metastatic Urothelial Cancer (mUC) After Platinum (PLT)-Based Therapy. Annals of Oncology (2020) 31 (suppl_4): S550-S550. 10.1016/annonc/annonc274
Petrylak DP, Tagawa ST, Jain RK, et al. Early Results of TROPHY-U-01 Cohort 2: Sacituzumab Govitecan (SG) in Platinum-Ineligible Patients (pts) With Metastatic Urothelial Cancer (mUC) Who Progressed After Prior Checkpoint Inhibitor (CPI) Therapy. J Clin Oncol. 2020; 38 (suppl; abstr 5027).
Tagawa ST, Balar A, Petrylak DP, Grivas P, et al. Initial Results From TROPHY-U-01: A Phase 2 Open-Label Study of Sacituzumab Govitecan in Patients (Pts) With Metastatic Urothelial Cancer (mUC) After Failure of Platinum-Based Regimens (PLT) or Immunotherapy. Annals of Oncology (2019) 30 (suppl_5): v851-v934.10.1093/annonc/mdz394.
Tagawa ST, Petrylak DP, Grivas P, et al. TROPHY-u-01: A phase II open-label study of sacituzumab govitecan (IMMU-132) in patients with advanced urothelial cancer after progression on platinum-based chemotherapy and/or anti-PD-1/PD-L1 checkpoint inhibitor therapy. J Clin Oncol.2019; 37 (suppl; abstr TPS3153).
Rugo HS, Bardia A, Tolaney SM, Arteaga C, et al. TROPiCS-02: phase 3 study of Sacituzumab Govitecan (IMMU-132) in relapsed/refractory hormonal receptor-positive (HR+) human epidermal growth factor receptor 2 negative (HER2-) metastatic breast cancer (MBC). San Antonio Breast Cancer Symposium; December 10 -14, 2019; San Antonio, TX.
Cardillo TM, Sharkey RM, Rossi DL, et al. Synthetic lethality exploitation by an anti-Trop-2-SN-38 antibody-drug conjugate, IMMU-132, plus PARP inhibitors in BRCA1/2-wild-type triple-negative breast cancer. Clin Cancer Res. 2017;23:3405-3415
Chang CH, Wang Y, Zalath M, et al. Combining ABCG2 inhibitors with IMMU-132, an anti-Trop-2 antibody conjugate of SN-38, overcomes resistance to sn-38 in breast and gastric cancers. Mol Cancer Ther. 2016;15(8):1910-1919
Cardillo TM, Govindan SV, Sharkey RM, et al. Sacituzumab govitecan (IMMU-132), an anti-trop-2/SN-38 antibody-drug conjugate: characterization and efficacy in pancreatic, gastric, and other cancers. Bioconjug Chem. 2015;26:919-931
Goldenberg DM, Cardillo TM, Govindan SV, et al. Trop-2 is a novel target for solid cancer therapy with sacituzumab govitecan (IMMU-132), an antibody-drug conjugate (ADC). Oncotarget.2015;6:22496-22512
Sharkey RM, McBride WJ, Cardillo TM, et al. Enhanced delivery of SN-38 to human tumor xenografts with an anti-Trop-2-SN-38 antibody conjugate (sacituzumab govitecan).Clin Cancer Res. 2015;21:5131-5138
Cardillo TM, Govindan SV, Sharkey RM, et al. Humanized anti-Trop-2 IgG-SN-38 conjugate for effective treatment of diverse epithelial cancers: preclinical studies in human cancer xenograft models and monkeys. Clin Cancer Res. 2011;17:3157-3169
Govindan SV, Stein R,* Qu Z, Chen S,* Andrews P,* Ma H, Hansen HJ, Griffiths GL, Horak ID, Goldenberg DM. Preclinical therapy of breast cancer with a radioiodinated humanized anti-EGP-1 monoclonal antibody: advantage of a residualizing iodine radiolabel. Breast Cancer Res Treat. 2004;84:173-182
Sharkey RM,* Karacay H,* Govindan SV, Goldenberg DM. Combination radioimmunotherapy and chemoimmunotherapy involving different or the same targets improves therapy of human pancreatic carcinoma xenograft models. Mol Cancer Ther. 2011;10:1072-1081
Dotan E, Cohen SJ, Starodub AN, et al. Phase I/II trial of labetuzumab govitecan (anti-CEACAM5/SN-38 antibody-drug conjugate) in patients with refractory or relapsing metastatic colorectal cancer. J Clin Oncol. 2017;35:3338-3346.Labetuzumab Govitecan Preclinical Publications
Govindan SV, Cardillo TM, Moon SJ, Hansen HJ, Goldenberg DM. CEACAM5-targeted therapy of human colonic and pancreatic cancer xenografts with potent labetuzumab-SN-38 immunoconjugates. Clin Cancer Res. 2009;15:6052-61.
Sharkey RM, Govindan SV, Cardillo TM, et al. Selective and concentrated accretion of SN-38 with a CEACAM5-targeting antibody-drug conjugate (ADC), labetuzumab govitecan (IMMU-130). Mol Cancer Ther. 2018;17:196-203.
Govindan SV, Cardillo TM, Rossi EA, Trisal P, McBride WJ, Sharkey RM, Goldenberg DM. Improving the therapeutic index in cancer therapy by using antibody-drug conjugates designed with a moderately cytotoxic drug. Mol Pharm. 2015;12:1836-1847.
Sharkey RM,* Juweid M,* Shevitz J, Behr T,* Dunn R,* Swayne LC,* Wong GY,* Blumenthal RD,* Griffiths GL, Siegel JA, Leung SO, Hansen HJ, Goldenberg DM. Evaluation of a complementarity-determining region-grafted (humanized) anti-carcinoembryonic antigen monoclonal antibody in preclinical and clinical studies. Cancer Res. 1995;55:5935s-5945s.
Cardillo TM, Govindan SV, Zalath MB, et al. IMMU-140, a novel SN-38 antibody-drug conjugate targeting HLA-DR, mediates dual cytotoxic effects in hematologic cancers and malignant melanoma. Mol Cancer Ther. 2018;17:150-160.
Stein R,* Gupta P, Chen X,* Cardillo TM, Furman RR,* Chen S,* Chang C-H, Goldenberg DM. Therapy of B-cell malignancies by anti-HLA-DR humanized monoclonal antibody, IMMU-114, is mediated through hyperactivation of ERK and JNK MAP kinase signaling pathways. Blood. 2010;115:5180-5190.
Stein R,* Qu Z, Chen S,* Solis D, Hansen HJ, Goldenberg DM. Characterization of a humanized IgG4 anti-HLA-DR monoclonal antibody that lacks effector cell functions but retains direct antilymphoma activity and increases the potency of rituximab. Blood. 2006;108:2736-2744.
Moon S-J, Govindan SV, Cardillo TM, D’Souza CA, Hansen HJ, Goldenberg DM. Antibody conjugates of 7-ethyl-10-hydroxycamptothecin (SN-38) for targeted cancer chemotherapy. J Med Chem. 2008;51:6916-6926.Book Chapter/ Review Articles Highlighting Immunomedics’ SN-38 ADCs
Govindan SV, Cardillo TM, Goldenberg DM. Topoisomerase inhibitors as antibody-drug conjugate payloads, In: Cytotoxic payloads for antibody-drug conjugates, 2019; pp 164-184; Thurston DE and Jackson PJ (eds); Royal Society of Chemistry, London, UK (Publisher).